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Fibroblast growth factorChick and mouse embryos with heritable deﬁciencies of aggrecan exhibit severe dwarﬁsm and premature
death, demonstrating the essential involvement of aggrecan in development. The aggrecan-deﬁcient
nanomelic (nm) chick mutant E12 fully formed growth plate (GP) is devoid of matrix and exhibits markedly
altered cytoarchitecture, proliferative capacity, and degree of cell death. While differentiation of
chondroblasts to pre-hypertrophic chondrocytes (IHH expression) is normal up to E6, the extended
periosteum expression pattern of PTCH (a downstream effector of IHH) indicates altered propagation of IHH
signaling, as well as accelerated down-regulation of FGFR3 expression, decreased BrdU incorporation and
higher levels of ERK phosphorylation, all indicating early effects on FGF signaling. By E7 reduced IHH
expression and premature expression of COL10A1 foreshadow the acceleration of hypertrophy observed at
E12. By E8, exacerbated co-expression of IHH and COL10A1 lead to delayed separation and establishment of
the two GPs in each element. By E9, increased numbers of cells express P-SMAD1/5/8, indicating altered
BMP signaling. These results indicate that the IHH, FGF and BMP signaling pathways are altered from the very
beginning of GP formation in the absence of aggrecan, thereby inducing premature hypertrophic chondrocyte
maturation, leading to the nanomelic long bone growth disorder.© 2009 Elsevier Inc. All rights reserved.Introduction
Growth and development of the long bones of the skeleton is a
complex, multi-step, precisely-timed and spatially-organized process
regulated by several genetic, endocrine and mechanical programs.
During limb formation, mesenchymal cells migrate to establish areas
of high cell density in a condensation process; at this stage the
position, number and shape of the future skeletal elements is
determined. After differentiation of mesenchymal cells into chondro-
cytes, development of cartilage occurs by both interstitial and
appositional growth into the shape of future bone (Cohen, 2000a,b;
Karsenty, 2003). Endochondral bone growth occurs in the epiphyseal
growth plate (GP), a specialized tissue found at the ends of long bones.
In this process, chondrocytes become arranged in columns parallel to
the longitudinal axis of the long bones and differentiate, forming
histologically distinct zones. Closest to the epiphyseal end of the GP
are resting chondrocytes, which are metabolically less active. Next is a
zone of proliferation in which cells only divide with cleavage planes
perpendicular to the longitudinal axis of the long bone, hence the
length of the column of cells increases (Cohen, 2000a,b). After several
mitoses, chondrocytes mature, become encased in an extracellular
matrix (ECM) and acquire a characteristic round morphology (pre-
hypertrophic). In a further transition, the chondrocytes cease toniversity of Chicago, 5841 S.
1 773 702 9234.
artz).
l rights reserved.divide, gradually increase in size and eventually hypertrophy.
Ultimately, the hypertrophic chondrocytes die by apoptosis and are
replaced by mineralized bone and bone marrow via vascular invasion,
resorption of the cartilaginous matrix and recruitment of osteoblasts
that deposit a bone-speciﬁc matrix (Horton, 1993; Horton et al., 1998;
Olsen et al., 2000). This general paradigm is followed in both avian
and mammalian GP development, with the exception that vascular
penetration and GP erosion is less uniform in chick (Bruder and
Caplan, 1989).
Concomitant with this series of morphological events, a highly-
regulated gene expression proﬁle is observed, involving an increas-
ingly numerous array of growth regulators, transcription factors and
signaling molecules that presumably are responsible for orchestrating
the cellular andmolecular events that direct the formation,maturation
and eventual destruction of the transient cartilage, as well as for
regulating expression of several matrix components that deﬁne the
milieu surrounding the chondrocytic cell-types as they differentiate
(Wagner and Karsenty, 2001). Of documented importance to this
process is the expression of ECM molecules which provide structural
support to the chondrocytes and likely either interact directly with the
cells or create a milieu which affects passage from cell to cell of vital
growth factors and signaling molecules. The ECM is composed
predominantly of several types of collagens and proteoglycans,
hyaluronan and link protein, with smaller amounts of other matrix-
speciﬁc proteins (Schwartz and Domowicz, 2002a). Collagens provide
the ECMwith strength, elasticity and cohesionwhile the proteoglycans
confer compressibility, resilience and form a gel-like medium that
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al., 1991), acting as a selective diffusion barrier (Quinn et al., 2001).
During skeletal development different proteoglycans are
expressed in a highly-deﬁned pattern that is regulated spatially and
temporally. Versican, a large chondroitin sulfate proteoglycan (CSPG),
is expressed in the undifferentiated mesenchymal cells of the early
limb bud and during the onset of pre-chondrogenic condensation,
then disappears with the differentiation to chondrocytes (Kimata et
al., 1986). Concomitantly with the down-regulation of versican, a
dramatic up-regulation of aggrecan, a biochemically similar member
of this gene family, occurs during the establishment andmaturation of
the chondrocyte phenotype (Schwartz et al., 1993). Although other
minor proteoglycans are produced by chondrocytes, aggrecan repre-
sents the bulk of the proteoglycan expressed during endochondral
differentiation. Aggrecan interacts with ﬁlaments of hyaluronan to
form aggregates which are further stabilized by interaction with link
protein (Hardingham and Muir, 1973). Chondrocytes organize their
pericellular matrix, composed largely of type II collagen and aggrecan;
its assembly and retention at the surface of the cells is facilitated by
the aggrecan–hyaluronan aggregate interacting with a cell-surface
receptor, CD44 (Knudson and Knudson, 2001).
Mutations that affect the highly-organized processes of cartilage
formation and endochondral ossiﬁcation result in a host of inherited
skeletal disorders, known as the chondrodysplasias. There are multi-
ple loci at which mutations may affect proteoglycan-based pheno-
types; i.e., genes for the core proteins, glycosaminoglycan-modifying
and polymerizing enzymes, and signaling, growth and transcription
factors that regulate synthesis and secretion of proteoglycans
(Schwartz, 2002). In particular, mutations in the aggrecan gene in
humans have been associatedwith spondyloepimetaphyseal dysplasia
with premature and severe osteoarthritis (Gleghorn et al., 2005;
Tompson et al., 2009). Despite the continuing identiﬁcation of
proteoglycan defects associated with several chondrodysplasias
(Schwartz, 2004; Schwartz and Domowicz, 2002a), there remains
limited understanding of the underlying molecular mechanisms
which lead to the altered GP phenotype.
We elucidated the ﬁrst aggrecan core protein mutation in the
homozygous recessive nanomelic (nm) chick (Li et al., 1993), which
results in an extreme form ofmicromeliawith reduced head and trunk
size and gross skeletal abnormalities including extremely short, broad
and malformed limbs. Homozygous nm embryos exhibit a rather
homogeneous GP cell population, devoid of matrix and with loss of
growth zone demarcation (Schwartz and Domowicz, 1998, 2002b,
2004). The nm mutants are morphologically indistinguishable from
the wild type prior to embryonic day 8 (E8), and the fact that the
number of skeletal elements is not changed indicates that this
mutation does not alter the early determinants of the pattern
formation process, but rather interferes with the growth of individual
elements. These morphological observations suggest several possible
consequences of thematrix deﬁciency underlying the disorganized GP
in the nm mutant; e.g. normal chondrocyte differentiation may be
altered because aggregan is a key factor in controlling maturation, or
the process of bone formation may be accelerated because aggrecan
acts as an anti-angiogenic factor in the matrix. Alternatively, the
observed phenotype may be due an altered diffusion or selective-
permeability barrier because of the absence of aggrecan in the ECM
which could affect growth factor diffusion and/or morphogen
gradient formation. To begin to address these issues, the gene
expression patterns of relevant matrix and GP-speciﬁc molecules
were analyzed concomitantly with a detailed analysis of the GP
developmental steps which are inﬂuenced by the lack of aggrecan.
Materials and methods
Wild type (wt) fertilized White Leghorn chicken eggs were
purchased from Sharp Sales (West Chicago, IL). Fertilized eggs fromnanomelia heterozygote (+/nm) crosses were provided by the
Department of Animal Genetics, University of Connecticut (Storrs,
CT). Eggs were incubated at 37.9 °C at 60% humidity in a Midwest
incubator with automatic egg turning, regularly hatching at day-21 of
incubation. In all experiments, both White Leghorn embryos and
embryos of normal progeny from the nanomelia heterozygote crosses
(ﬂock-mates) were tested as controls. No differences between these
two set of controls were found in the levels, distributions and
developmental regulation of any messages assayed by in situ
hybridization or immunocytochemistry. Affected embryos (−/−)
could be detected morphologically by E8 while early identiﬁcation
was done by genotyping (Li et al., 1993).
Immunocytochemical staining
Limbs from chick embryos were ﬁxed at 4 °C with fresh 4%
paraformaldehyde in phosphate-buffered saline (PBS), then
embedded in parafﬁn for sectioning. Tissue sections (10 μm) were
dewaxed in xylene, rehydrated by passage through a series of
decreasing-percentage ethanol solutions, then treated with 5 mg/ml
bovine serum albumin for 1 h to block nonspeciﬁc binding prior to
overnight incubation with the anti-aggrecan monoclonal antibody
S103L (1:100 dilution). After extensive washes with PBS, sections
were incubated for 2 h in alkaline phosphatase-conjugated secondary
antibody solution (AP-anti-rat IgG from Pierce diluted 1:100), washed
again with PBS, mounted in Eukitt mounting medium, and photo-
graphed with a Nikon microscope. For P-SMAD1/5/8 and P-SMAD2
immunostaining, Chemicon antibodies were used after unmasking
epitopes by treating the sections with 0.1 M citric acid pH 6 for 15 min
in themicrowave. The peroxidase signal was ampliﬁedwith tyramide-
FITC.
P-SMAD-positive nuclei from limb sections were counted and the
counts standardized for the number of DAPI-positive nuclei using
ImageJ software. Data was analyzed for statistical signiﬁcance using
the Student's t-test.
PCNA immunostaining was performed following a similar proce-
dure using the PC10 antibody from DAKO (1:250 dilution). Photo-
graphs (6–8) of the hypertrophic and proliferative zones from
multiple limb elements were used for quantiﬁcation. Statistical
analysis was performed using the Student's t-test. Apoptosis was
assessed in situ using the TUNEL method (Tdt-mediated dUTP nick-
end labeling) (Brunner, 1998). Alternatively, for proliferation assays
BrdU (1.6 mg/100 μl) was applied to the vitelline membrane of E18
eggs 3 h prior to tissue harvest. Tissue was then ﬁxed, embedded,
sectioned and processed for immunocytochemistry using an anti-
BrdU IgG (BD Bioscience) primary antibody and alkaline phosphatase-
conjugated anti-rabbit IgG (Roche, Germany) secondary antibody.
Von Kossa's stain
Limbs ﬁxed in 4% paraformaldehyde/PBSweremounted in parafﬁn
and 10 μm sections were cut and treated with 2% silver nitrate
solution; the matrix-bound calcium was then reduced by exposure to
strong light and replaced with silver deposits (Thompson and Hunt,
1966). Sections were counterstained with hematoxilin.
mRNA in situ hybridization
E12 chick limbs were ﬁxed in 4% paraformaldehyde/PBS overnight.
The tissue was sunk in 20% sucrose/10% formalin in PBS, embedded in
10% gelatin/20% sucrose and sectioned at a thickness of 40 μm. Sections
were mounted on Superfrost/Plus microscope slides (Fisher) pre-
coatedwith poly-L-lysine. Slideswere processed for non-radioactive in
situ hybridization as previously described (Domowicz et al., 2008).
Two-color ﬂuorescence in situ hybridization (FISH) was performed on
E9 limb sections as previously described (Domowicz et al., 2008).
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Lysates from E6 wt and nm cartilage were prepared in RIPA buffer
with phosphatase and protease inhibitors (PhosSTOP and Complete
from Roche). Total protein was normalized using the BCA assay
(Pierce) and equal amounts of protein were subjected to 10% SDS-
PAGE and electrotransferred to nitrocellulose membrane at 150 mA
overnight. Primary antibodies used are anti-β-actin (mouse IgG,
1:1000, Sigma) and anti-Phospho-p44/42 MAP Kinase (Rabbit IgG
1:1000, Cell Signaling), and the secondary antibody was a HRP-
conjugated goat anti-mouse IgG and anti-rabbit IgG (Pierce),
respectively. Signal was detected using the SuperSignal West Dura
Extended Duration Substrate (Pierce) and visualized and quantiﬁed
by Quantity One software (Bio-Rad).
cDNAs
Aggrecan gene expression was analyzed with riboprobes derived
from a 690-bp fragment from exon 12 of the chicken aggrecan gene,
obtained as previously described (Domowicz et al., 2008) Probe
fragments for IHH, COL10A1, COL2A1, osteopontin and osteocalcin
were obtained by PCR from a cDNA library generated using random
hexamer primers, E12 chick cartilage mRNA and SuperscriptII-Reverse
Transcriptase (Invitrogen). The speciﬁc PCR primers used were
GACTGCGTGGTGAGAGAGG-3′ and TGGCTCTAACGGCATGC-3′ for
COL2A1; ATGCTCGCAGTGCTAAAGCCT-3′ and AGAAGTGGAGCA-
TAATGGGGG-3′ for osteocalcin; CATTGCTGCTGCATGGCC-3′ and
GCTGGCGTCGACGGCGG-3′ for osteopontin; CCAACGTGCCCGA-
GAAGA-3′ and AGTGGATGTGCGCCTTGGA-3′ for IHH; GGGTGAAGAA-
GGGG-3′ and TGGTAAACCTGGC-3′ for COL9A1; AGAAGAATGAAC-3′
and ATCCCAGAAGG-3′ for COL10A1. Chick PTHrP receptor and BMP6
cDNA fragments were generated in similar fashion using degenerate
primers based on the known human and mouse sequences.
Degenerate oligonucleotides were designed with the aid of the Blocks
and CODEHOP (COnsensus-DEgenerate Hybrid Oligonucleotide Pri-
mers) programs (http://blocks.fhcrc.org/) (Rose et al., 1998). The
speciﬁc primers used were TCCTGAACGACGCCgayatggtnatg-3′ and
TGGGGGCGATGAtccartcytgcc-3′ for BMP6 and CCCGACTACATCTAC-
GACTTCaaycayaargg-3′ and GCACCGGCCGgcrttngtytc-3′ for PTHrP
receptor. PCR products were ligated into the pCRII dual-promoter
vector plasmid from Invitrogen. Sequencing of the cloned gene
fragments was performed with an ABI PRISM 377XL sequencer
(Perkin Elmer) by the University of Chicago Cancer Center DNA
Sequencing facility. Riboprobes incorporating DIG-labeled nucleotides
were synthesized from linearized plasmid templates with T7 or SP6
polymerase (Roche). As controls, in situ hybridizations using probes
for neurocan and brevican messages, which are not expressed in
limbs, were performed with negative results.
Semi-quantitative RT-PCR
OneStep RT-PCR mix (Qiagen) was used to amplify target RT-PCR
fragments according to the manufacturer's protocol, using 0.5 μg of
total wt or nm E6 limb or E12 limb cartilage RNA. Cycling parameters
for each PCR fragment were optimized by varying the annealing
temperature, extension time and number of cycles (25–35) so that the
ampliﬁcation was in the exponential range. Ampliﬁed DNA was
electrophoresed in on a 1.5% agarose gel, then imaged and quantiﬁed
using the Bio-Rad ChemiDoc XRS imaging system.
Embryonic limb explant cultures
Chicken tibia were stripped of skin and muscles by gentle rubbing
against sterile ﬁlter paper and cultured in BGJ-B medium (Invitrogen)
with penicillin/streptomycin (Invitrogen) and 0.1% BSA (Minina et al.,
2001). Tibias from the same embryo were kept as matched pairsmach. Members of each pair was cultured with or without 10 μM
cyclopamine (Incardona et al., 1998). After 48 h in culture, explants
were ﬁxed, photographed and processed for mRNA in situ hybridiza-
tion. Total tibial growth length was determined using ImageJ.
Results
GP development in day-12 aggrecan-deﬁcient nanomelic chick
In the epiphyseal GPs of mid-development (day 12) chick embryos,
chondrocytes at progressive stages of differentiation are organized
into well established architecturally distinct zones. Hematoxylin–
eosin staining of embryonic day-12 chick limbs highlights abnormal
morphological aspects of the proliferative and hypertrophic zones of
nm epiphyseal cartilage compared to wild type (wt) (Figs. 1A and B)
including: i) disruption of normal cytoarchitecture; ii) higher cell
density per unit area; iii) absence of matrix between cells; iv)
condensed nuclei, and v) smaller hypertrophic chondrocytes. The
chick aggrecan-speciﬁc monoclonal antibody S103L exhibits abundant
membrane-associated and ECM staining in the proliferative zone of wt
cartilage, but only very faint (intracellular) staining in nm limb. In the
hypertrophic zone, S103L-stained aggrecan is also abundant and
predominantly extracellular in wt, while there is no reaction product
in the mutant (Figs. 1C and D), verifying complete absence of the
aggrecan molecule.
Since cell-number homeostasis as well as the normal architecture
of the GP result directly from a balance between cell proliferation and
apoptosis, the rate of cell division and extent of cell death were
independently assessed in the aggrecan-deﬁcient mutant. When E12
wt limb sections were stained with an antibody to proliferation cell
nuclear antigen (PCNA), which marks cells in the S-phase of the cell
cycle, a large number of proliferative-zone cells were stained, while
very few hypertrophic-zone cells were PCNA-positive. Interestingly,
intense staining with the PCNA antibody in both proliferative and
hypertrophic chondrocytes was observed in the nm mutant (Figs. 1E
and F). Upon quantitative analysis, statistically signiﬁcant increases
were found in the number of S-phase cells per unit area sampled
among nm proliferative (3-fold) and hypertrophic (20-fold) chon-
drocytes, compared to the respective wt regions (Fig. 1, I, PCNA-
positive). Taking into account the increased number of cells per unit
surface area in the nm cartilage compared to the wt (Fig. 1, total
numbers), approximately 1 of every 5 chondrocytes in the wt
proliferative zone undergoes cell division in a given time period
while 1 of every 4 chondrocytes does so in the nm proliferative zone.
While it is rare to observe a PCNA-positive cell in the wt hypertrophic
zone, 1 of every 3 nm hypertrophic chondrocytes expresses PCNA.
These results indicate an increased proliferative rate for nm
chondrocytes in the absence of aggrecan in the matrix. Qualitatively,
TUNEL staining of wt limbs showed thatmore cell death occurs among
hypertrophic than proliferative zone chondrocytes, while in nm
mutants there was a slight increase in the number of apoptotic cells
in the hypertrophic zone and an unexpectedly greater increase in the
proliferative zone (Figs. 1G and H).
The signiﬁcant abnormalities in chondrocyte morphology and
homeostasis are reﬂected in the striking growth retardation observed
in the E12 nm GP. (Fig. 2). Most notably, E12 nm tibias are
approximately one-third the length of their wt counterparts, and
the structure of the limbs are grossly distorted (Fig. 2A). GP zone
demarcation in day-12 wt chick tibias is clearly indicated by
expression of mRNAs for alpha 1 type IX collagen (COL9A1) (Figs.
2A and B), alpha 1 type II collagen (COL2A1) and alpha 1 type X
collagen (COL10A1) (Fig. 2B). Except for the hypertrophic chondro-
cytes, all zones of the GP express COL9A1 and COL2A1, albeit to
differing degrees. The terminal state of wt chondrocyte differentiation
(hypertrophic) is accompanied by a signiﬁcantly different proﬁle of
gene expression, typiﬁed by strong expression of COL10A1 (a marker
Fig. 1. Patterns of cell death and proliferation inwild type (wt) and nanomelic (nm) embryos. Images depict proliferative (A, C, E, G) and hypertrophic (B, D, F, H) chondrocyte zones
from E12 wt and nm tibial limb sections. Parafﬁn sections were stained with hematoxylin–eosin (A, B) and immunostained with S103L antibody (C, D). Proliferative cells were
detected with anti-PCNA antibody (E, F) and apoptotic cells were detected by TUNEL staining (G, H). Scale bar: 50 μm. (I) Chondrocyte proliferation inwt and nm E12 limbs. Average
numbers of PCNA-positive cells per ﬁeld were determined by immunocytochemistry and total numbers of cells from phase-contrast photographs of the same ﬁelds. A total of 6–8
0.07 mm2 ﬁelds each from wt and nm proliferative and hypertrophic zones were counted. ⁎pb0.0001.
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of COL9A1 and COL2A1 mRNAs (Fig. 2B). Further comparison of GP
size in nm and wt E12 tibias on the basis of the extents of their
COL10A1, COL9A1 and COL2A1 expression domains indicates that all
regions are proportionally reduced in the mutant, again reﬂecting the
dimensional differences in the long bones. Mapping of GP zones using
these three well-characterized collagen components shows that states
of chondrocyte differentiation are tightly coordinated with gene
expression as previously illustrated (Sandell et al., 1991, 1994; Wai et
al., 1998), and thus can be used to correlate the expression patterns of
other genes important to GP development in normal and chondrody-
strophic limbs. In particular, when the expression pattern of aggrecan
across the wt chick GP was analyzed (Fig. 2B), the levels of aggrecan
expression vary with the state of chondrocyte differentiation; resting
chondrocytes exhibit a low, steady level of aggrecan expression, while
much higher levels of expression are observed for proliferative and
pre-hypertrophic chondrocytes, followed by markedly reduced levels
in the mature hypertrophic chondrocytes, similar to the COL2A1 and
COL9A1 patterns. In contrast, signiﬁcantly reduced levels of aggrecan
mRNA expression are detected in all regions of nm cartilage, in
agreement with previous ﬁndings by Northern analysis (Li et al.,1993). Despite the drastic reduction of aggrecan expression in nm
cartilage, COL2A1 and COL9A1 are still strongly expressed, although in
signiﬁcantly reduced domains. Also note that even though levels of
aggrecan message are largely reduced in wt hypertrophic chondro-
cytes, immunostaining with the aggrecan antibody S103L is still high
(Fig. 1D). This persistence has been observed in mouse as well
(Shibata et al., 2003) and likely is due to the slow turnover of the
aggrecan protein (Mok et al., 1994).
Changes in regulatory-gene expression in aggrecan-deﬁcient GP
The expression patterns of certain gene products, i.e. signaling
molecules, growth factors and transcription modulators, previously
shown to regulate epiphyseal GP formation were also assessed. While
in serial sections of wt tibias (Fig. 4) there is clear demarcation of the
areas expressing COL10A1 (characteristic of hypertrophic chondro-
cytes) and Indian hedgehog (IHH) (characteristic of pre-hypertrophic
chondrocytes), bothmarkers are expressed in the same area in the nm
mutant, making it impossible to distinguish the hypertrophic and pre-
hypertrophic zones (Figs. 2B, 3A and 4). Even though the expression
domain of IHH is greatly reduced in the mutant, levels of IHH mRNA
Fig. 2. Expression of matrix protein genes. (A) Expression of collagen type IX (COL9A1) in E12 tibia sections fromwt and nm chicks detected by in situ hybridization. Three sections
from each of 10 embryos were analyzed with consistent results. (B) Higher magniﬁcation of E12 limb sections hybridized with probes for collagen type IX (COL9A1), aggrecan
(AGC1), collagen type X (COL10A1), and collagen type II (COL 2A1). In situ hybridizations with DIG-labeled probeswere performed on 40 μm tibia sections. When necessary, cartilage
element limits were outlined. P: proliferative zone; PH pre-hypertrophic zone; H: hypertrophic zone. Scale bar: 1 mm.
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(OPN), a marker of late hypertrophic chondrocytes and osteoblasts, is
partially co-expressed with COL10A1 in wt embryos, while in nm
epiphyseal cartilage transcripts for OPN also co-localize with those for
COL10A1 and IHH, and are present at increased levels in sites
associated with secondary ossiﬁcation (Fig. 3A, arrow). Osteocalcin
(BGLAP), a marker of osteoblasts, is localized in comparable patterns
in the trabecular bone associated with both wt and nm GPs. BMP6, a
member of the bone morphogenetic protein family that is expressed
predominantly in pre-hypertrophic chondrocytes (Solloway et al.,
1998; Vortkamp et al., 1996), is observed in a pattern that partially
overlaps that of IHH in wt embryos (Fig. 3A). A narrow band of BMP6
expression persists in nm GP, most likely marking newly-differen-
tiated hypertrophic chondrocytes. However, BMP6 expression also
overlaps the distal region of IHH expression and completely overlaps
the area of COL10A1 expression. Previous studies have shown that the
parathyroid hormone-related peptide (PTHrP) receptor (PTH1R) is
expressed throughout the GP but at much higher levels in pre-
hypertrophic chondrocytes proximal to the proliferative zone, while
IHH is expressed at the pre-hypertrophic/hypertrophic zone bound-
ary (Amizuka et al., 1994; Lee et al., 1995). Our gene expression screen
in wt E12 embryos showed that PTH1R is indeed localized to pre-hypertrophic chondrocytes proximal to the proliferative zone and the
adjacent perichondrium in wt E12 embryos (Fig. 3A). In nm embryos
of the same age, a small region of PTH1R expression persists at the
borders of the hypertrophic region near the perichondrium, but the
level of PTH1R in the pre-hypertrophic chondrocytes seems to be
reduced. When levels of PTH1R were analyzed in wt and nm E12
cartilage by semi-quantitative RT-PCR no signiﬁcant differences in the
expression levels were observed (Fig. 3B). As well, levels of the main
ligand of PTH1R, PTHLH were also comparable in wt and nm E12
cartilage (Fig. 3B).
To determine whether the abnormal expression of IHH affects its
function, we compared the expression of the hedgehog effector Patched
(PTCH) in wt and nm E12 cartilage in serial sections probed with IHH,
COL10A1 and FGFR3 (Fig. 4). As shownpreviously (compare Figs. 2B and
3A) the normal largely non-overlapping pattern of COL10A1 and IHH is
lost in the nmmutant. The expression of PTCH inwt GP is localized in a
pattern similar to that described for proliferative and hypertrophic
zones and in the perichondrium at the level of IHH expression in
mammalian limbs (St-Jacques et al., 1999); PTCH expression in the nm
limbs remains strong in the perichondrium at the level of the bone
collar, but in the proliferative zone it is disorganized, irregular and
narrow. Furthermore, the distance from the epiphyseal perichondrium
Fig. 3. Expression proﬁles of regulatory genes. (A) Upper images in each group: expression of Indian hedgehog (IHH), bone morphogenic protein 6 (BMP6), PTHrP receptor (PTH1R),
osteopontin (OPN) and osteocalcin (BGLAP) detected by in situ hybridizations using DIG-labeled probes in 40 μm tibia sections fromwt and nm E12 embryos. Scale bar: 1 mm. Each
lower row image shows a higher magniﬁcation of the boxed area in the respective upper row photograph. Asterisks (⁎) indicate chondrocyte expression of PTH1R. Arrows indicate
secondary ossiﬁcation sites in nm GP. PH: pre-hypertrophic zone; H: hypertrophic zone. LH: late hypertrophic zone. Scale bar: 150 μm. (B) Semi-quantitative RT-PCRs for IHH, PTH1R
and parathyroid hormone-related peptide (PTHLH) performed on wt and nm E12 cartilage RNA.
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alterations in the IHH gradient. Expression of FGFR3, which has been
described as encompassing the proliferative and hypertrophic zones in
themammalianGP (Colvin et al.,1996),was found tobe similar in thewt
chick GP. In the nm growth plate, as observed for PTCH expression, the
distance from the epiphyseal perichondrium to the FGFR3 domain is
expanded compared to wt (Fig. 4, see brackets).
To assess whether the observed changes in matrix and signaling
molecule expression alter the extent of calciﬁcation in nm bone, von
Kossa staining for calcium deposits and trabecular cytoarchitecture
was performed on nm and wt E12 limbs. Normal, although somewhat
more compacted, calciﬁed trabeculae were observed in nm limbs,indicating that calciﬁcation proceeds normally in the absence of
aggrecan (Supplemental Fig. 1).
Formation of the GP in the absence of aggrecan
Evaluation of the fully formed GP (E12) indicated signiﬁcant
morphological, molecular and signaling differences between wt and
the aggrecan-deﬁcient nm mutant (Figs. 1–4), but provided little
mechanistic insight into how these aberrant phenotypes arise. To
investigate the possibility that expression of COL10A1 and IHH in the
E12 nm GP could be due to accelerated hypertrophy in the absence of
aggrecan and to determine the progression of phenotypic and
Fig. 4. Comparative expression proﬁles. Expression of FGFR3, COL10A1, IHH, and PTCH (1 and 2) mRNAs, detected by in situ hybridizations using DIG-labeled probes in serial 40 μm
tibia sections fromwt and nm E12 embryos. Numbered insets are close-ups of the areas indicated in the PTCH expression panel. Double arrows indicate the extent of the epiphyseal
expression of PTCH. Brackets indicate the distance between the epiphyseal domain of expression and the perichondrium. Lines mark the perichondrium boundaries.
Fig. 5. Establishment of a GP without aggrecan. Expression patterns of aggrecan (AGC1) (A, B, I, J), Indian hedgehog (IHH) (C, D, K, L), collagen type X (COL10A1) (E, F, M, N) and
osteopontin (OPN) (G, H, O, P) in E7 (A–H) and E8 (I–P) limb sections fromwild type (wt) (A–C, E, G; I, K, M, O) and nanomelic (nm) (B, D, F, H; J, L, N, P) chicks. In situ hybridizations
with gene-speciﬁc DIG-labeled RNA probes were performed on 40 μm sections. Arrows designate areas enlarged in corner insets of G, H, O and P.
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249M.S. Domowicz et al. / Developmental Biology 329 (2009) 242–257genotypic changes during limb development in the aggrecan-deﬁcient
mutants, the expression patterns of cartilage-speciﬁc markers were
analyzed by in situ hybridization on serial sections from the E7–8
developmental interval, the critical period when hypertrophic
chondrocytes ﬁrst appear (Fig. 5). In E7 (stage HH31) wt embryos,
aggrecan was expressed strongly and fairly uniformly along the
cartilage anlage (Fig. 5A). IHH expression was detected in the middle
of the aggrecan expression domain and was clearly absent from distal
portions of the cartilage elements (Fig. 5C). Very faint expression of
COL10A1 (Fig. 5E), a marker of hypertrophic chondrocytes, was
detectable in a few cells in the central region of the IHH expression
domain, and OPN, a marker of late hypertrophic chondrocytes and
osteoblasts, was barely detectable in the perichondrium surrounding
the IHH-expressing domain in wt embryos (Fig. 5G arrow and inset).
By E8 in wt embryos, aggrecan expression encompasses the entire
element with an obvious diminution in the center, presumably
representing initiation of the hypertrophic zone in each element.
Strong aggrecan expression is detected distally as the two pre-
hypertrophic domains begin to separate (Fig. 5I), leading to the
formation of dual proliferative and pre-hypertrophic zones. Note that
the areas with the highest levels of aggrecan (AGC1) mRNA are
coincident with IHH expression (Figs. 5I, K), which remains true up to
E12 (Figs. 3, 4). The IHH expression domain also splits into two regionsFig. 6.Maturation of the nm GP. DAPI-counterstained, Indian hedgehog (IHH) and collagen X
tibia sections. Fluorescent in situ hybridizations (FISH) with gene-speciﬁc DIG-labeled RNA
temporally enhanced in the nanomelic (nm) growth plate while the area expressing exclusby E8 (Fig. 5K), each distal to the central expression domain of
COL10A1 (Fig. 5M). The expansion in length andwidth of the twin IHH
domains is approximately three-fold in each dimension, reﬂecting the
signiﬁcant growth of the wt element during this 24 h period. The
expression of OPN in E8 wt limbs is more distinct in the
perichondrium and encompasses the entire length of the IHH-
expressing domain (Fig. 5O, arrow and inset).
In nm embryos at the very early stage (E7), there was a slight
reduction in size of the skeletal elements but no other gross
phenotypic differences compared to wt, although there was no
expression of AGC1 mRNA (Fig. 5B). The extent of the IHH expression
domain was comparable betweenwt and nm and IHH expression was
somewhat reduced in intensity in the mutant (Figs. 5C, D). Most
surprisingly, expression of COL10A1 (Fig. 5F) was strongly up-
regulated, exhibiting a domain of mRNA expression that nearly
overlapped the entire IHH region (Fig. 5D), indicating precocious
differentiation to the hypertrophic phenotype. At this early stage there
was also moderate up-regulation of OPN expression localized to the
perichondrium of nm cartilage elements, spanning the length of the
IHH/COL10A1 domain, also suggesting accelerated hypertrophy and
ossiﬁcation (Fig. 5H arrowand inset). At E8, the size of the nmcartilage
element had begun to diminish (40% reduction) in width and length
compared to wt. Also in contrast to wt, division of the IHH expression(COL10A1) gene expression and merged composite images, from E7 and E8 nm and wt
probes were performed on 40 μm sections. The IHH and COL10A1 co-expression area is
ively IHH is reduced in the E8 nm GP (white brackets in the E8 merge images).
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mutants by E8 (Fig. 5L), and the overall expansion of the IHH
expression domains between E7 and E8 in nm embryos was less
than 30% (Figs. 5D, L). COL10A1 continued to exhibit a robust
expression domain at E8 which still mostly overlapped that of IHH
(Fig. 5N), again indicating accelerated differentiation to hypertrophic
chondrocytes in nm embryos. Furthermore, there was demonstrable
GP maturation in nm E8 cartilage elements as evidenced by the
signiﬁcantly increased and nearly overlapping expression patterns of
OPN and COL10A1 (Figs. 5N, P arrow and insert). By E8, osteocalcin
started to be detected in the periosteum and the levels were
comparable between wt and nm GP (data not shown).
Since very limited information is available regarding expression of
IHH and COL10A1 during the initial establishment of the GP, we
attempted to distinguish between two possible mechanisms that
could explain these early phenotypic changes in the aggrecan-null
model using ﬂuorescent in situ hybridization (FISH) of individual
cells: i) whether normal chondrocytes that differentiate from the pre-
hypertrophic to the hypertrophic state require down-regulation of
IHH expression before up-regulation of COL10A1 can occur; or, ii)
whether an intermediate zone is generated in which the same cells
express both markers at the same time, making this process a
transitional event rather than a switch from one stage to the next. We
then asked whether this process is affected in the nm mutant.
Confocal images of both E7 and E8wt GP showed robust and restricted
chondrocyte expression of IHH and COL10A1 (Fig. 6), and a very
limited number of cells displaying co-expression (yellow cells). At E7,
the nm IHH expression domain was only slightly smaller than in wt,
but by E8 the IHH expression domainwas signiﬁcantly reduced in size
(see also Fig. 5). As also shown in Fig. 5, COL10A1 expression in theFig. 7. Initiation of hypertrophy in nanomelic GP. (A) Expression of IHH in E6 wt and nm
limbs visualized by whole mount in situ hybridizations. (B) The areas of IHH expression
were quantiﬁed for the ulna (U), radius (R) and digits 2 (D2), 3 (D3), and 4 (D4) in 10
limbs each from nm and wt embryos using the NIH ImageJ software package. (C)
Consistent levels of IHH were observed in E6 limbs RNA by semi-quantitative RT-PCR.
Fig. 8. Nanomelic growth plate at E6. Expression patterns of IHH, PTCH1, FGFR3, and
BMP6 in E6 limb sections fromwt and nm chick embryos. The mRNAs were detected by
in situ hybridization with DIG-labeled RNA probes (signal was assigned the pseudo-
color green). Sections were counterstained with DAPI.
Fig. 10. Phosphorylated MAPK is increased in E6 nm cartilage. (A) Immunoblotting
analysis showing levels of phosphorylatedMAPK (Erk), and β-actin as a loading control,
in E6 wt and nm cartilage lysates. (B) Relative levels of phosphorylatedMAPK to β-actin
were quantiﬁed in three independent experiments. Data was evaluated for statistical
signiﬁcance using the Student's t-test. ⁎pb0.04.
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expression did not grow. However, in contrast to wt, co-expression in
the mutant GP, observed by confocal microscopy was extensive, to the
extent that only a very small area expressed IHH exclusively (E8 wt
and nmmerge panels, brackets). Thus, it would appear that in normal
GP development IHH expression is down-regulated prior to the up-
regulation of COL10A1, allowing only a minimal number of cells to be
in a transitional stage. Further, the ability of chondrocytes to down-
regulate the expression of IHH during differentiation of pre-
hypertrophic to hypertrophic, appears to be inﬂuenced by the
presence or absence of an aggrecan-rich matrix.
Since reduced expression domains for IHH were observed in the
nm mutant as early as E7 (Figs. 5, 6), we determined whether even
earlier events, i.e. differentiation of chondroblasts to pre-hypertrophic
chondrocytes in E6 embryos were affected by the lack of aggrecan
expression by analyzing levels of IHH via whole mount in situ
hybridization. This approach offers the advantage that the earliest
stages of development are detectable, since limb differentiation occurs
in a proximal-to-distal sequence and the distal condensations of the
limb are at the least mature stages of differentiation. The area and
apparent intensity of IHH expression in the ulna, radius and digits 2, 3
and 4 were similar between wt and nm at E6 (Fig. 7A). Although
patterns of IHH expression appear normal, potential differences in the
IHH expression domains were quantiﬁed in two sets of ten
independent embryos each using ImageJ software (Fig. 7B), and
overall IHH mRNA levels were assessed by semi-quantitative RT-PCR
on wt and nm E6 RNA (Fig. 7C). No signiﬁcant differences were
consistently observed by either approach, indicating that the initial
temporal differentiation of chondroblasts to pre-hypertrophic chon-
drocytes is normal in the nm mutant.
To determine whether IHH signaling topography is affected in the
early nm embryo, we monitored the expression of the hedgehog
effector Patched (PTCH) in E6 limbs (Fig. 8). While expression ofFig. 9. Early decreased cell division in pre-hypertrophic chondrocytes. After 3 h of BrdU
incorporation (1.6 mg/100 μl), dividing cells were visualized in tibia sections from wt
and nm (A, B, red) E6 embryos after IHH mRNA was detected by FISH (C, D, green).
Sections were counterstained with DAPI. White lines indicate the areas enlarged in the
merged images (E, F). Numbers of BrdU-positive cells were quantiﬁed in ten
comparable but independent areas from both wt and nm embryos (G). Data was
evaluated for statistical signiﬁcance using the Student's t-test. ⁎pb0.008.
Fig.11. Interaction of IHH and FGF signaling. Matchedwt and nm E8 tibias were cultured
for 2 days with (+) or without (−)10 μM cyclopamine. (A) Total tibial length at the end
of the culture time was measured using the ImageJ program, and data were evaluated
for statistical signiﬁcance using the Student's t-test for correlated samples. ⁎pb0.001.
(B) Expression of FGFR3, IHH, and COL10A1 detected by in situ hybridizations using
DIG-labeled probes in serial 40 μm sections fromwt and nm cultured tibia explants with
or without cyclopamine treatment.
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of PTCH expression in the mutant limb was broader, indicating an
expanded area of initial IHH signaling when aggrecan is not being
expressed in the cartilage element at this early stage of GP
formation. Changes in BMP6 and FGFR3 expression were also
evident at this early stage (Fig. 8). The pattern of BMP6 expression
is similar in wt and nm limbs but it appears to be somewhat down-
regulated in the mutant (Fig. 8). Interestingly, while FGFR3 is
expressed all along the cartilage element and in the perichondrium
at the level of the developing periosteum in E6 wt elements,
expression of FGFR3 was already strongly down-regulated in the
middle of the E6 nm element. Since FGFR3 has been implicated as a
regulator of cell division during cartilage development (Ornitz and
Marie, 2002), we analyzed cell division capacity in the early GPs of
E6 embryos by BrdU incorporation. At this stage, cell division in the
wt elements was seen to recede in the area where IHH expression
was beginning (Figs. 9A, C, E). Furthermore, in contrast to our results
from the fully formed GP (E12), cell division in E6 epiphyseal
cartilage was down-regulated in the nm mutant qualitatively (Figs.
9A, B) and quantitatively (Fig. 9G); as well, the recession of the cell
division zone in the middle of the element was also accelerated
(Figs. 9B, F). Since these results could be indicative of de-regulation
of FGF signaling, we biochemically analyzed one of the recognized
downstream indicators of FGF signaling in the GP, phosphorylated
ERK (de Frutos et al., 2007). Western blot analysis of wt and nm E6
cartilage homogenates using an anti-phospho P42/44 MAPK anti-
body yielded a single 43 kDa band (Fig. 10A), as has been previously
described for other chick tissues (Garcia et al., 2008). Quantiﬁcation
of phosphorylated ERK levels in E6 nm cartilage revealed an elevated
level relative to that of wt cartilage (Fig. 10B).
Since our results thus far are indicative of de-regulation of both
FGF and IHH signaling in the nmmutant, we investigatedwhether IHH
signaling could modulate FGFR3 transcription using exogenous
inhibition of IHH signaling in an organ explant culture system (Minina
et al., 2002). We treated wt and nm E8 tibia explant cultures with
cyclopamine over a 48 h period and analyzed the resulting expression
of COL10A1, IHH and FGFR3. An 11% and 7% reduction, respectively, in
the length of wt and nm tibias in the presence of cyclopamine was
observed concomitantly with higher expression of COL10A1 in both
wt and nm limbs (Fig. 11). These observations are commensurate with
the reported outcomes of similar mouse limb explant experiments
(Minina et al., 2002). We also observed reduced FGFR3 expression
domains in both wt and nm tibias when IHH signaling was inhibited
(Fig. 11). Even though there is genetic evidence that FGFR3 regulates
IHH expression (Colvin et al., 1996), these data indicate that the
opposite is also possible.
TGF-beta and BMP signaling pathways
Since BMP6 and BMP2 have been implicated as negative regulators
of hypertrophy (Yoon et al., 2006), we analyzed the activation of these
pathways by determining levels of phospho-SMAD1/5/8 (P-SMAD1/5/
8) in wt and nm GP. We also measured the levels of P-SMAD2, since
other matrix-affected mutants such as the chondroitin-4 sulfotrans-
ferase-1 gene trap showed up-regulation of TGFβ signaling (Kluppel
et al., 2005). Measurable levels of P-SMAD2 were not detected at E6,
prior to the initiation of the maturation process (not shown).
However, by E9, P-SMAD2 immunoreactivity was observed through-
out the whole skeletal element (Fig. 12A), and quantiﬁcation of
positive cells in the hypertrophic zone showed no statistical
differences between the wt and nm GPs (Fig. 12B). In contrast, P-
SMAD1/5/8 was expressed preferentially in the hypertrophic zone
(Fig. 12A), and a signiﬁcant increase in the number of positive cells
was seen in the nm GP (Fig. 12B). These results may reﬂect a futile
attempt by BMP signaling to slow down the maturation process in the
nm mutant GP.Gene expression in nm and wt chondrocyte cultures
To determine whether the defect in maturation of nm pre-
hypertrophic chondrocytes is intrinsic to the chondrocytes or
dependent on alteration of a signaling pathway regulated by the
cytoarchitecture and matrix composition of the GP, we analyzed the
maturation potential of nm chondrocytes in culture. A well-character-
ized primary culture model of spontaneous differentiation (Ferguson
et al., 2000; Grimsrud et al., 1999; Iwamoto et al., 1993; Volk et al.,
1998) established from E14 wt and nm sterna was used for this
purpose. High levels of extracellular aggrecan were detected with the
S103L antibody in wt cultures, while no extracellular expression of
aggrecan in nm chondrocyte cultures was observed (Fig. 13A). As
expected, wt cultures expressed high levels of both aggrecan and
Fig. 12. Hypertrophic chondrocytes expressing P-SMAD1/5/8 are increased in nm GP
compared to wt. (A) Immunocytochemical staining with P-SMAD 2 and P-SMAD1/5/8
speciﬁc antibodies showed comparable levels of P-SMAD2 and increased levels of P-
SMAD1/5/8 in hypertrophic chondrocytes of E9 nm GP with respect to wt. Sections
were counterstained with DAPI. (B) The numbers of P-SMAD2- and P-SMAD1/5/8-
positive cells relative to total numbers of cells (DAPI-positive nuclei) in seven
independent ﬁelds each from wt and nm limbs were determined using ImageJ
software. Data was analyzed for statistical signiﬁcance using the Student's t-test.
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minimal aggrecan expression in nm cell cultures (Fig. 13B), paralleling
the in vivo observations (Fig. 5) and indicating that nm chondrocytes
are healthy and maintain normal morphology in culture. Fewer cells
expressing COL10A1 and OPN mRNA, relative to the number of cells
expressing COL2A1, were observed in both wt and nm cultures (Fig.
13B); however, when the amounts of COL10A1 and OPN transcripts
relative to the levels of GAPDH mRNA in the cultures were measured
to account for the total mass of cells (Fig. 13C), nm chondrocytes
appear not to be in an advanced state of differentiation as we
described in vivo (Fig. 5). To determine whether this was due to
increased cell division in the nm chondrocytes, BrdU incorporation
and MTT assays were performed. Both a higher rate of cell division, as
indicated by BrdU-positive incorporation (30% increase), and a greater
number of cells, as reﬂected by increased MTT levels (40% increase),
were observed in the nm cultures (Fig. 13D).
To determine whether apoptotic pathways were also activated in
the nm cultures as observed in vivo, analyses of caspase-3 and
caspase-8 activities were performed. Activation of caspase-3 is a
central event in the apoptotic process upon which numerous path-ways converge, while caspase-8 activation is believed to be one of the
initiation caspases at the beginning of the signaling cascade (Chen and
Wang, 2002; Liu et al., 1996; Orth et al., 1996; Thornberry et al., 1997).
In the nm cultures both activities were up-regulated approximately 2-
fold with respect to thewt cultures, indicating increased prevalence of
apoptosis in the nm culture (Fig. 13E). Together, these data suggest
that the nm cell proliferation capacity but not the differentiation
potential is at least partially intrinsic to the chondrocyte.
Discussion
Recently identiﬁed hereditary skeletal disorders associated with
extracellular matrix genemutations in humans and animalmodels are
providing insights into the roles that the affected molecules play in
skeletal development and growth (Schwartz, 2004). However, most of
these studies have analyzed the fully developed mature GP of matrix-
deﬁcient models (Maddox et al., 1997; Savontaus et al., 1996; Wai et
al., 1998; Watanabe and Yamada, 1999); therefore, little insight has
been provided on the function of thematrix during GP formation or its
inﬂuence on GP cell signaling. One recent study of a gene trap
mutation in the chondroitin-4-sulfotransferase 1 (C4st1) gene which
causes down-regulation of 4-O-sulfated chondroitin synthesis identi-
ﬁed a severe chondrodysplasia that is characterized by strong up-
regulation of TGFβ signaling and down-regulation of BMP signaling
(Kluppel et al., 2005). Furthermore, in the brachymorphic (bm)
mouse, where levels of CS sulfation are reduced due a natural
inactivating mutation of one of the isoforms of PAPS synthetase,
PAPSS2 (Kurima et al., 1998), alterations in IHH signaling have been
observed (Cortes et al., in press), demonstrating that modiﬁcation of
the chondroitin sulfate component of aggrecan can adversely affect
distinct signaling pathways during GP morphogenesis.
We have now obtained intriguing data from the avian aggrecan-
deﬁcient nm model, which revealed severe alterations in the genetic
and developmental programs occurring in the nm GP concomitant
with appearance of atypical morphology (Figs. 2–4). Strikingly, the
absence of aggrecan, the major proteoglycan component of cartilage
matrix, is accompanied by dysregulation of several genes previously
shown to be critical to the maturation process of hypertrophic
chondrocytes and osteogenesis. First, although there appears to be
both initiation and progression through the normal states of
differentiation by nm chondrocytes (i.e., to expression of COL10A1),
the hypertrophic zone is small and disorganized by the time a mature
GP (E12) is formed. Secondly, based on the expression of a number of
GP markers, the zones of pre-hypertrophic and hypertrophic cells that
characterize a normal GP appear to overlap in the nmmutant (Figs. 1–
3); a phenomenon which starts at the earliest stages of GP formation
(E7) concomitant with the lack of aggrecan accumulation (Figs. 5, 6).
Thirdly, both in vivo and in vitro, lack of aggrecan in the ECM is
associated with signiﬁcant differences in numbers of cells in mutant
versus wt GP caused by ﬂuctuations in the proliferative and apoptotic
pathways (Figs. 1 and 9), a phenomenon that also changes as GP
maturation proceeds.
A role for IHH dysregulation underlying these changes in the nm
GP was veriﬁed by analysis of PTCH expression in the mature growth
plate which showed a narrow epiphyseal gradient in the nm mutant,
suggesting that the lack of matrix could impair the normal IHH
gradient (Fig. 4). The gene expression patterns of modulators critical
to GP development in the E12 nm chick, in particular the overlapping
expression of COL10A1, BMP6 and IHH mRNAs which obscures the
normal distinctions between the pre-hypertrophic and hypertrophic
regions, suggest acceleration of hypertrophy (Figs. 2–4). Also, strong
expression of OPN mRNA, a marker of late hypertrophic chondrocytes
and osteoblasts, observed in a pattern that completely overlaps that of
COL10A1 mRNA, suggests that acceleration of hypertrophy induces
precocious bone formation in the nm mutant. Interestingly, advanced
hypertrophy was already observed in the mutant when the
254 M.S. Domowicz et al. / Developmental Biology 329 (2009) 242–257hypertrophic chondrocytes are ﬁrst detected in wt GP (E7–8) (Fig. 5).
Most importantly, IHH-expressing cells rapidly proceed to hypertro-
phy (expression of COL10A1) without down-regulating expression ofIHH (Fig. 6), indicating loss of control of this critical switch.
Consequently, i) the nm GP does not exhibit the characteristic pre-
hypertrophic and hypertrophic zone demarcation; ii) separation and
255M.S. Domowicz et al. / Developmental Biology 329 (2009) 242–257appositional growth of the twin GPs of each element is delayed; iii)
vascular invasion becomes accelerated (up-regulation of OPN) and
osteogenesis occurs prematurely; and iv) longitudinal as well as
lateral growth is retarded.
Since the IHH-expressing domain is reduced from E7 onward, we
tested whether this deﬁciency was driven by an even earlier (E6)
abnormal setting of the IHH expression domain. Although, IHH
appears to be turned on normally in the condensations (Fig. 7),
arguing against precocious maturation of chondroblasts to pre-
hypertrophic chondrocytes, the domain of expression of the hedgehog
effector PTCH is broader in the perichondrium of the E6 nm elements,
indicating a disturbance in the range of IHH signaling (Fig. 8) beyond
the area where aggrecan is normally expressed, thus potentially
modifying a key source of GP signaling, the developing periosteum.
Several other important changes were observed in the aggrecan-
deﬁcient mutant at this critical period of early GP development. In
contrast to the increased cell division observed during GP maturation
in the nm mutant (E12), early stage (E6) nm epiphyseal cartilage
exhibits a slightly lower rate of cell division. This cell division arrest
observed in the area where IHH is expressed may be only slightly
accelerated in the nm GP even though the levels of FGFR3, an
important regulator of cell division and hypertrophic differentiation
(Ornitz and Marie, 2002), are already strongly down-regulated in the
forming pre-hypertrophic zone of the nm mutant (Fig. 8).
The changes observed in FGFR3 transcription levels and localiza-
tion are difﬁcult to explain since little is known about FGFR3 mRNA
regulation in the developing GP. It is possible that the altered IHH
signaling could elicit changes in FGF signaling, since our organ culture
data (Fig. 11) indicate changes in patterning and levels of FGFR3
expression when IHH signaling was inhibited by cyclopamine.
Alternatively, is possible that early down-regulation of FGFR3 in the
nm maturation zone might be an indicator of FGF signaling mis-
regulation, as it has been reported that FGF-2 could down-regulate
FGFR3 expression in culture (Ling et al., 2006). Both possibilities are
supported by our ﬁnding that levels of phosphorylated ERK are up-
regulated in E6 nm cartilage, as a result of either saturation of FGFR3
activation due to its down-regulation or alteration of FGF2 diffusion
due to the lack of matrix. Thus, increased FGF signaling could explain
the early down-regulation of cell division in the nm GP and the early
depletion of FGFR3 in the nm pre-hypertrophic zone. This depletion of
FGF signaling then could push IHH-expressing precursor cells to
prematurely differentiate to hypertrophic chondrocytes, quickly
depleting the pool of IHH-expressing cells and further driving cells
into hypertrophy. Although only moderate reduction in BMP6
expression in the forming GP (E6) was observed, later (E9) increases
in the level of BMP signaling in the hypertrophic zone was seen as
determined by increased SMAD 1–5–8 phosphorylation (Fig. 12);
perhaps this occurs in response to the accelerated hypertrophy, since
BMPs have been described as negative regulators of chondrocyte
maturation (Minina et al., 2002, 2001). Increased BMP signaling could
be a reaction directed toward moderating the acceleration, or
alternatively, simply a reﬂection of the accelerated terminal differ-
entiation observed in the nm GP. Thereafter, the combined effects on
the developing periosteum and continued down-regulation of FGFR3
ultimately could reduce FGF signaling, thereby accelerating cell
division. It has been suggested that FGF and BMP signaling act inFig. 13. Expression of matrix component genes by wt and nm chondrocytes in culture. (A)
permeabilization, so as to detect only extracellular aggrecan. (B) Expression of AGG, C
chondrocytes from wt and nm E14 sterna. Scale bar: 35 μm. (C) The bar graphs show level
wt and nm chondrocyte cultures. Quantiﬁcation was performed using the same in situ hyb
the ﬂuorescent substrate MUP. Determinations were performed on triplicate wells for each
and nm chondrocytes. Cell viability was determined by assessing mitochondrial activity
incorporation levels for chondrocytes from wt and nm E14 sterna maintained in culture for
apoptotic pathway was assessed by determining the speciﬁc activities of caspase-3 and ca
The results are shown as the mean±SD(bars), pb0.005 for the MTT and proliferation
chondrocytes were culture for 8 days.antagonistic and independent fashions upstream of IHH/parathyroid
hormone-like protein signaling to deﬁne the zone where pre-
hypertrophy will be initiated and also to regulate the rate of
progression to hypertrophy. While FGF signaling is a negative
regulator of cell division and suppresses hypertrophy, BMP signaling
acts in parallel to IHH to induce proliferation and hinder hypertrophic
differentiation (Minina et al., 2002). This last point has been contested
in the literature since knock-outs of Bmpr1a in mouse suggest that
BMP signaling is required for completion of terminal hypertrophic
differentiation (Yoon et al., 2006). In the nm mutant, these three
integrated signaling pathways appear to lose their balance-controlling
inﬂuence after the initial IHH domain of expression is formed, possibly
due to absence of a matrix in which to establish the respective
gradient ﬁelds.
The lack of aggrecan in the nm matrix also may affect access by
growth factors necessary for signaling between the perichondrium
and the developing chondrocytes. Since part of the altered phenotype
was retained in dispersed cell cultures, i.e. increased cell division and
cell death, altered diffusion, or availability of signaling molecules in
the nm mutant could be a factor. However, accelerated differentiation
was not observed when the cytoarchitecture was destroyed by plating
single cells from nm cartilage into culture, indicating that positional
information and zonal signaling paradigms, as well as the integrity of
the matrix and an intact perichondrium, are likely critically important
to establishment of the hypertrophic phenotype (Figs. 12, 13). As well,
we have not ruled out the contribution of changes caused by
mechanical stresses due to muscle contraction in the developing
limb; however, since clear modiﬁcations of signaling molecule
expression patterns are observed as early as E6, when limb size in
the wt and nm are comparable, it is expected that these inﬂuences are
secondary to the defects in GP formation.
Lastly, aggrecan-induced matrix deﬁciency may lead to premature
and/or increased invasion of the nm GP hypertrophic region by blood
vessels and osteoblasts; indeed, an anti-angiogenic function for the
aggrecan matrix has been proposed (Fenwick et al., 1997). GP
chondrocytes produce angiogenic factors (e.g., bFGF and VEGF) that
recruit endothelial cells to migrate towards the hypertrophic cells
(Carlevaro et al., 2000; Gerber et al., 1999), but this process may be
altered in the absence of aggrecan, a known diffusion barrier to many
factors in cartilage (Grodzinsky, 1983). The developmental expression
pattern of aggrecan mRNA throughout the GP of normal limbs
indicates that different states of chondrocyte differentiation require
different levels of aggrecan in the extracellular matrix. The fact that
pre-hypertrophic chondrocytes express the highest levels of aggrecan
message in the wt GP is congruent with our ﬁnding in the nm mutant
that the lack of aggrecan throughout the GP affects predominantly the
transition of chondrocytes from the pre-hypertrophic to the hyper-
trophic phenotype. Also, the altered PTCH gradient in the nm limb
suggests that aggrecan is essential for establishing a proper IHH
gradient; these data are supported by the observations that IHH binds
chondroitin sulfate chains in vitro and that in the undersulfated CSPG
matrix of the bm mouse GP, a reduction in the extent of the IHH
gradient has also been observed (Cortes et al., in press). If IHH long
range diffusion is impaired in matrix depleted of the major CSPG,
aggrecan, such as in the nm limb, it may explain an increased PTCH
signal towards the developing periostium at E6 and a reduced PTCHWt and nm chondrocyte cultures immunostained with S103L antibody (red) without
OL2A1, COL10A1 and OPN messages detected by in situ hybridization in cultured
s of AGC1, COL2A1, COL10A1 and OPN transcripts relative to levels of GAPDH mRNA in
ridization protocol but replacing the NBT/BCIP substrate of alkaline phosphatase with
probe sample. Bars represent standard deviations. (D) Cell-proliferation in cultured wt
using the MTT assay and cell proliferation measured by determining 4-hour BrdU-
6 days. (E) Apoptotic pathways in cultured wt and nm chondrocytes. Activation of the
spase-8 using the ﬂuorogenic substrates Ac-DEVD-AFC and Ac-IETD-AFC, respectively.
assays and pb0.001 for both caspase assays. In all the experiments dissociated
256 M.S. Domowicz et al. / Developmental Biology 329 (2009) 242–257gradient in the fully formed GP (E12). Early changes in the IHH
gradients could trigger changes in the other signaling pathways, or
alternatively other ligand gradients could also be inﬂuenced by the
altered matrix. In sum, our results indicate that an aggrecan-rich
matrix is necessary for appropriate morphogen gradient formation;
thereby indirectly modulating the coordination of several distinct
signaling pathways during GP morphogenesis. These ﬁndings take us
a step closer to understanding the pathogenesis of chondrodysplasias,
especially human disorders associated withmutations in the aggrecan
gene (Gleghorn et al., 2005; Tompson et al., 2009).
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